Form 4: CalciMedica Director Allan Shaw Granted Significant Stock Options Following Shareholder Approval

CalciMedica, Inc. Director Allan Shaw was granted a total of 54,844 stock options with exercise prices of $1.53 and $1.65, following the company's stockholder approval of an amended equity incentive plan.

Summary

• Allan Shaw, a Director of CalciMedica, Inc. (CALC), was granted a total of 54,844 derivative securities in the form of Director Stock Options (Right to Buy) on June 24, 2025.
• The grants include 10,000 shares with an exercise price of $1.53, vesting 1/12th monthly over one year following March 26, 2025, and expiring on April 22, 2035.
• An additional 8,594 shares were granted with an exercise price of $1.53, which are immediately exercisable and expire on April 22, 2035.
• A grant of 26,250 shares was made at an exercise price of $1.53, vesting 1/9th monthly over one year following April 1, 2025, and expiring on April 22, 2035.
• Finally, 10,000 shares were granted with an exercise price of $1.65, vesting 1/12th monthly over one year following June 24, 2025, and fully vesting by the Company's 2026 annual meeting of stockholders, expiring on June 23, 2035.
• These option grants were initially approved by the Board of Directors on April 23, 2025, contingent on stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan (the 'Amended 2023 EIP'), which was obtained on June 24, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard and expected corporate action of granting equity compensation to a director, which aligns management interests with shareholders. There are no negative implications from this specific filing.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance and value creation.
• The stockholder approval of the Amended 2023 Equity Incentive Plan demonstrates shareholder support for the company's compensation strategy and ability to attract and retain talent.

Future Outlook

The document indicates future vesting events for the granted stock options, with various monthly vesting schedules extending over a one-year period from their respective start dates, and one grant fully vesting by the Company's 2026 annual meeting of stockholders.

Management Comments

• The option grants were approved by the Board of Directors of CalciMedica, Inc. on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan.
• The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of equity compensation to a director. It does not provide information on broader industry trends or competitive landscape, but reflects standard corporate governance practices for incentivizing leadership.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon option exercise, but also benefit from the alignment of director incentives with company performance.
• Director (Allan Shaw): Receives equity compensation, incentivizing his continued contribution to the company's success.

Next Steps

• Continued vesting of the granted stock options according to their respective schedules.
• The Company's 2026 annual meeting of stockholders, which is a milestone for the full vesting of one option grant.

Key Dates

Keywords

CalciMedica, CALC, SEC Form 4, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Corporate Governance